Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Cadonilimab (AK104) plus radiotherapy in ESCC after progression on PD-(L)1 therapy
ChiCTR2600121031Phase 2Completed
- Sponsor
- Sichuan Cancer Hospital & Institute
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital & Institute. Primary endpoints: Objective Response Rate (ORR) and Progression-Free Survival (PFS). Started Mar 2026; status: completed.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600121031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121031.